Xiangyi Ma
YOU?
Author Swipe
View article: MEIS1-mediated Apoptosis via TNFR1 in Endometriosis
MEIS1-mediated Apoptosis via TNFR1 in Endometriosis Open
Abnormal apoptosis both maintains endometrial cell growth and induces endometrial pathogenesis. The etiology of endometriosis is unclear and no treatment is curative. Therefore, the aim herein was to identify genes involved in the pathogen…
View article: Comparison and analysis of deep learning models for discriminating longitudinal and oblique vaginal septa based on ultrasound imaging
Comparison and analysis of deep learning models for discriminating longitudinal and oblique vaginal septa based on ultrasound imaging Open
Convolutional neural network-based model (ConvNeXt-B) shows promising capability of discriminating longitudinal and oblique vaginal septa ultrasound images and is expected to be introduced to clinical ultrasonographic diagnostic system.
View article: Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications
Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications Open
View article: Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer
Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer Open
The mortality of ovarian cancer (OC) has long been the highest among gynecological malignancies. Although OC is considered to be an immunogenic tumor, the effect of immunotherapy is not satisfactory. The immunosuppressive microenvironment …
View article: Optical molecular imaging in cancer research: current impact and future prospect
Optical molecular imaging in cancer research: current impact and future prospect Open
Cancer has long been a major threat to human health. Recent advancements in molecular imaging have revolutionized cancer research by enabling early and precise disease localization, essential for effective management. In particular, optica…
View article: Molecular Biological Research on the Pathogenic Mechanism of Retinoblastoma
Molecular Biological Research on the Pathogenic Mechanism of Retinoblastoma Open
Retinoblastoma (RB) is the most common intraocular malignant tumor in children, primarily attributed to the bi-allelic loss of the RB1 gene in the developing retina. Despite significant progress in understanding the basic pathogenesis of R…
View article: WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses
WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses Open
Introduction: Recurrence signifies the primary mortality factor in patients suffering from endometrial cancer, with few efficacious treatments currently available for recurrent cases. This research investigates the anti-tumoral capa…
View article: Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study
Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study Open
View article: Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer? Open
Endometrial cancer (EC) is increasingly undermining female health worldwide, with poor survival rates for advanced or recurrent/metastatic diseases. The application of immune checkpoint inhibitors (ICIs) has opened a window of opportunity …
View article: Multi-omics characterization of cellular state diversity and bidirectional tumor-stroma/immune interactions in cervical squamous cell carcinoma
Multi-omics characterization of cellular state diversity and bidirectional tumor-stroma/immune interactions in cervical squamous cell carcinoma Open
Cervical cancer ranks as the fourth leading cause of cancer-related deaths among women, with low response rates to immune-checkpoint blockade (ICB). Here we conducted a multidimensional analysis encompassing single-cell RNA-seq (scRNA-seq)…
View article: Supplementary Figure Legend from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Figure Legend from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary Figure Legend
View article: Supplementary methods from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary methods from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary methods
View article: Data from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Data from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Purpose:Tumor periphery and lymph nodes of tumor-induced lymphangiogenesis often abundantly express VEGFR-3. In our previous study, we identified a 5-amino acid peptide named TMVP1, which binds specifically to VEGFR-3. The objective of thi…
View article: Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Open
Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
View article: Supplementary Fig S1 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Fig S1 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
The expression of VEGFR-3 detected by IF (A) and western blot (B) in LEC, LEC(shVEGFR-3) and HUVECs.
View article: Supplementary Figure Legend from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Figure Legend from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary Figure Legend
View article: Data from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Data from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Purpose:Tumor periphery and lymph nodes of tumor-induced lymphangiogenesis often abundantly express VEGFR-3. In our previous study, we identified a 5-amino acid peptide named TMVP1, which binds specifically to VEGFR-3. The objective of thi…
View article: Supplementary Fig S2 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Fig S2 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
The saturation binding curve using the LECs with 1-40 nM of 68Ga-DOTA-TMVP1.
View article: Supplementary Tables from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Tables from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary Tables
View article: Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Open
Purpose: Tumor metastasis continues to be the major obstacle to cancer therapy and the leading cause of cancer-related death. Methods used to detect metastasis, especially occult metastases, have received a great deal attention. In …
View article: Supplementary Fig S1 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Fig S1 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
The expression of VEGFR-3 detected by IF (A) and western blot (B) in LEC, LEC(shVEGFR-3) and HUVECs.
View article: Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Open
Supplementary Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
View article: Supplementary Fig S2 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Fig S2 from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
The saturation binding curve using the LECs with 1-40 nM of 68Ga-DOTA-TMVP1.
View article: Supplementary methods from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary methods from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary methods
View article: Supplementary Tables from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Supplementary Tables from Primary Preclinical and Clinical Evaluation of <sup>68</sup>Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer Open
Supplementary Tables
View article: Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
Data from TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Open
Purpose: Tumor metastasis continues to be the major obstacle to cancer therapy and the leading cause of cancer-related death. Methods used to detect metastasis, especially occult metastases, have received a great deal attention. In …
View article: Artificial Intelligence in Cervical Cancer Screening and Diagnosis
Artificial Intelligence in Cervical Cancer Screening and Diagnosis Open
Cervical cancer remains a leading cause of cancer death in women, seriously threatening their physical and mental health. It is an easily preventable cancer with early screening and diagnosis. Although technical advancements have significa…
View article: Targeting regulated cell death in tumor nanomedicines
Targeting regulated cell death in tumor nanomedicines Open
Nanomedicines hold great potential in anticancer therapy by modulating the biodistribution of nanomaterials and initiating targeted oxidative stress damage, but they are also limited by the inherent self-protection mechanism and the evolut…
View article: Gonadotropin-releasing hormone agonist versus expectant management for treating multiple leiomyomas after myomectomy: the study protocol for a multicentre, prospective, randomised controlled clinical trial
Gonadotropin-releasing hormone agonist versus expectant management for treating multiple leiomyomas after myomectomy: the study protocol for a multicentre, prospective, randomised controlled clinical trial Open
Introduction Leiomyoma recurrence is a major concern for long-term myomectomy management, especially for multiple leiomyomas. Gonadotropin-releasing hormone agonist (GnRHa) is one of the most effective medications to reduce the volume of f…
View article: TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy
TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy Open
Our study provided a novel TP co-delivery platform for targeted chemotherapy of cervical cancer, which was promising to improve the therapeutic effcacy of TP and may also have application in other tumors.